Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Associated Therapies
- -
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 84
- Registration Number
- NCT02733419
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02582983
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02569502
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2021-11-23
- Target Recruit Count
- 11
- Registration Number
- NCT01836068
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Metabolic Effects of Enfuvirtide in Healthy Volunteers
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2008-04-14
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 15
- Registration Number
- NCT00657761
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 517
- Registration Number
- NCT00537394
- Locations
- 🇺🇸
Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States
🇺🇸Univ. of Rochester ACTG CRS, Rochester, New York, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
- Conditions
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT00487188
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 2
- Registration Number
- NCT00344760
- Locations
- 🇺🇸
University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
Fuzeon Viral Decay Pilot Study
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Canadian Immunodeficiency Research Collaborative
- Target Recruit Count
- 18
- Registration Number
- NCT00334022
- Locations
- 🇨🇦
Maple Leaf Medical Clinic, Toronto, Ontario, Canada
Study of Valproic Acid to Treat HIV Infected Adults
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 14
- Registration Number
- NCT00312546
- Locations
- 🇺🇸
University of North Carolina Memorial Hospital, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.